Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Other Working Capital Changes (2017 - 2025)

Cue Biopharma (CUE) has disclosed Other Working Capital Changes for 9 consecutive years, with -$4.9 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 100.95% to -$4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, down 29.44% year-over-year, with the annual reading at -$2.6 million for FY2025, 29.44% down from the prior year.
  • Other Working Capital Changes hit -$4.9 million in Q4 2025 for Cue Biopharma, down from $764000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $6.4 million in Q4 2021 to a low of -$6.3 million in Q3 2021.
  • Historically, Other Working Capital Changes has averaged $1802.4 across 5 years, with a median of $1500.0 in 2022.
  • Biggest five-year swings in Other Working Capital Changes: skyrocketed 1565.57% in 2021 and later tumbled 198.54% in 2024.
  • Year by year, Other Working Capital Changes stood at $6.4 million in 2021, then plummeted by 113.71% to -$880000.0 in 2022, then surged by 380.11% to $2.5 million in 2023, then crashed by 198.54% to -$2.4 million in 2024, then crashed by 100.95% to -$4.9 million in 2025.
  • Business Quant data shows Other Working Capital Changes for CUE at -$4.9 million in Q4 2025, $764000.0 in Q3 2025, and $2.3 million in Q2 2025.